Recent Biotech Buyouts at a Large Premium <pre> <b>Acquired Premium Deal iHub <u>Company</u> <u>Buyer</u> <u>to market</u> <u>value</u> <u>Date</u> <u>Reference</u></b> KOSN BMY 233% $190M 5/08 <a href='read_msg.asp?message_id=29647147'>#msg-29647147</a> COLY PFE 167% $165M 11/07 <a href='read_msg.asp?message_id=24600805'>#msg-24600805</a> IOMI Intercell 147% $190M 5/08 <a href='read_msg.asp?message_id=29232165'>#msg-29232165</a> TRC Ipsen 104% $660M 6/08 <a href='read_msg.asp?message_id=29795183'>#msg-29795183</a> SIRT GSK 85% $620M 4/08 <a href='read_msg.asp?message_id=28705020'>#msg-28705020</a> MLNM Takeda 53% $8.8B 4/08 <a href='read_msg.asp?message_id=28365383'>#msg-28365383</a></pre> <!--Beg_Sig--> <a href=http://www.investorshub.com/boards/board.asp?board_id=1418>Let’s talk biotech!</a> “The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”